Navigation Links
Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinson's Disease
Date:10/6/2009

WEST BLOOMFIELD, Mich., Oct. 6 /PRNewswire/ -- Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

The clinical trial will test whether gene transfer therapy is able to restore better mobility in Parkinson's patients who have lost responsiveness to drug therapy.

"The start of this clinical trial provides hope to a Parkinson's disease patient population that has had a long-standing need for better treatment options," says Henry Ford West Bloomfield Hospital neurologist Peter LeWitt, M.D.

Parkinson's disease is a degenerative disorder of the central nervous system that causes tremors and impairs a person's motor skills, speech, balance and posture. Its cause is unknown and it affects 1 percent to 2 percent of people over the age of 60.

Of the eight sites in the United States involved in the study, Henry Ford West Bloomfield Hospital is the only Michigan institution testing this experimental therapy.

A small region deep within the brain is the source for the symptoms of Parkinson's disease. When brain neurons in this part of the brain begin to die, these cells can no longer manufacture the molecule dopamine, a chemical critical for controlling movement.

Among patients with Parkinson's disease, the pace and extent of progression in neurologic deficits can greatly vary. The burden on quality of life spans a wide spectrum too, Dr. LeWitt says, from minimal discomfort and disability to marked impairment of capabilities such as independence, safety and communication.

Most current therapies and research approaches target dopamine to treat motor symptoms associated with Parkinson's disease. In contrast, the focus of the current gene therapy strategy is on increasing GABA, a brain neurotransmitter that regulates movement. In Parkinson's disease, GABA is reduced in an area of the brain called the subthalamic nucleus, causing it to be overactive. Investigators feel this might be a better way to help advanced Parkinson's disease.

For the clinical trial, the gene therapy product rAAV-GAD will be placed into the subthalamic nucleus by a surgical procedure. The gene transfer is done through a catheter that is removed shortly after its placement. Participants will be assessed post-treatment at multiple intervals. As an alternative to this experimental treatment, patients with advanced Parkinson's disease have the option of deep brain stimulation. This also involves a surgical procedure in which a pacemaker-like device is placed in the brain to help in control of Parkinson's disease symptoms.

LeWitt notes that the Henry Ford Parkinson's Disease and Movement Disorders Program is devoted to bringing the most promising therapies. This program is also working with experimental approaches for slowing progression of Parkinson's disease.

To learn more about the study, call 248-355-2452.

About Henry Ford Parkinson's Disease and Movement Disorders Program

The Henry Ford Parkinson's Disease and Movement Disorders Program is a Center of Excellence based in Southfield and at other Henry Ford locations. It provides treatment and research for Parkinson's disease, tremors, and other movement disorders. The Henry Ford program provides routine diagnostic services and treatment for Parkinson's disease, as well as several investigational studies for new treatments. Research carried out is searching for better treatments and possible ways to arrest the progression of Parkinson's disease, including neuroprotection strategies and an upcoming gene therapy clinical trial.

SOURCE Henry Ford Health System


'/>"/>
SOURCE Henry Ford Health System
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Henry Ford Macomb Hospital Deploys PerfectServe at Warren Campus to Improve Communication, Better Coordinate Care
2. Henry Ford Hospital Offers Free Prostate Cancer Screenings
3. Apollo PACS, Inc. Selected by Henry Ford Health System for Its Digital Pathology Solution
4. Henry Schein to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. 12th Annual Henry Schein Back-to-School Events Help 2,000 Underserved Children Return to the Classroom in Style
6. Henry M. Jackson Foundation names fellowship award winners
7. Atlanta Sleep Medicine Clinic Views Representative Henry Waxman's Denial of Restless Leg Syndrome as a Sign of General Lack of Awareness of the Sleep Disorder
8. CSC Signs $115 Million IT Services Renewal Agreement With Henry Ford Health System
9. Oklahoma Passes Comprehensive Tort Reform: Governor Brad Henry Signs Reform Legislation
10. Henry Ford Hospital: Unique Patient Study -- No Informed Consent
11. Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: